HK1 and myelodysplastic syndrome: Moreover, the combination of 3-BrPA with rapamycin (RAPA) has been an effective approach in preventing acute graft-versus-host disease by targeting HK and mTOR pathways in allo-HSCT patients, offering a novel treatment option to enhance MDS prognosis [81].